Craft
  • Home
  •  / Blueprint Medicines
Blueprint Medicines

Blueprint Medicines

Revenue

$180.1 M

FY, 2021

Market Capitalization

$3.7 B

2022-09-26

Blueprint Medicines Summary

Company summary

Overview
Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders. Its research technology combines bioinformatics, structural and cell biology, and a proprietary library of novel compounds. The company aims to help patients with genomically defined cancers, rare diseases, and cancer immunotherapy.
Type
Public
Founded
2011
HQ
Cambridge, MA, US | view all locations
Website
https://www.blueprintmedicines.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Jeffrey Albers

    Jeffrey Albers, Executive Chairman of the Board of Directors

  • Andrew Law

    Andrew Law, Director, Corporate Communications

  • Percy Carter, Chief Scientific Officer

    • Kate Haviland

    LocationsView all

    4 locations detected

    • Cambridge, MA HQ

      United States

      45 Sidney St

    • Amsterdam, NH

      Netherlands

      Gustav Mahlerplein 2

    • Lugano, TI

      Switzerland

      Via Emilio Bossi 6

    • Zug, ZG

      Switzerland

      Baarerstrasse 8

    Blueprint Medicines Financials

    Summary financials

    Revenue (Q2, 2022)
    $36.5M
    Gross profit (Q2, 2022)
    $31.7M
    Net income (Q2, 2022)
    ($159.7M)
    Cash (Q2, 2022)
    $173.4M
    Enterprise value
    $3.6B

    Footer menu